07:44 AM EDT, 08/26/2025 (MT Newswires) -- ZYUS Life Sciences ( ZLSCF ) on Tuesday said the first patient has been enrolled in its Phase 2a clinical trial investigating the treatment of oncology pain at the Centre Hospitalier de l'Universite de Montreal.

The UTOPIA-1 trial is a single-arm study investigating the safety and preliminary pain-relieving efficacy of Trichomylin softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

"Activating our first site and enrolling the first patient represents a significant step forward in advancing UTOPIA-1," said Brent Zettl, president and chief executive officer. "Trichomylin softgel capsules are designed to bridge the treatment gap between conventional therapies such as opioids and NSAIDs, offering a differentiated, evidence-based pharmaceutical approach for cancer pain."

Shares in ZYUS fell 4.1% in Canada yesterday.